Visby Management Reiterates Superior Offer to LCL Resources
Total Cash Consideration of AUD $15 Million + 1% NSR
Visby Urges Shareholders to Reject Tiger Gold Proposal
MEDELLIN, Colombia, June 2, 2025 /PRNewswire/ — Visby Management LLC ('Visby'), an international mine operator with operations in Colombia, would like to reiterate its superior, binding offer to acquire the Colombian assets of Los Cerros Limited (ASX: LCL) ('LCL') and is urging LCL shareholders to vote against the proposed transaction with Tiger Gold Corporation ('TGC') at the AGM on June 9, 2025. Visby also encourages shareholders to communicate their support for Visby's proposal at the upcoming LCL public webinar to be held on June 5, 2025.
Visby has submitted multiple binding offers to LCL to acquire the company's Colombian assets. In February 2025, Visby presented LCL with a superior offer and encouraged shareholders to vote against the latest TGC offer so that the company could consider it. Subsequently, 84% of shareholders at the February shareholder meeting voted against the TGC offer. Visby has since approached LCL with multiple offers superior to what TGC has offered but the LCL board has consistently refused to engage in discussions or allow shareholders to evaluate Visby's superior offers. Despite a clear message from shareholders in February, the LCL board is again recommending shareholders vote in favor of TGC at the upcoming June 9, 2025 AGM.
In hopes of getting support from understandably disgruntled shareholders, LCL scheduled a webinar for June 5, 2025 to presumably persuade shareholders on the TGC sale option. Upon learning of the webinar, Visby requested the opportunity to present its offer to shareholders in this same forum. The LCL board refused Visby's offer.
So that shareholders may make the most informed vote at the upcoming AGM, Visby would like to reiterate the following points:
The proposed TGC transaction is an option with only AUD $1m upfront, as LCL has stated on multiple occasions, and there is no guarantee TGC will deliver on the second payment due in eight months.
Despite an intentional lack of clarity from LCL's board, the TGC option does require shareholder approval.
The TGC agreement may be binding, but only as long as shareholders approve it.
With these points in mind, Visby would like to reiterate its binding AUD $15 million offer which includes:
Upfront payment of AUD $7.5 million (proof of funds available)
AUD $7.5 million on first gold pour
1% NSR
Visby is an experienced mine operator which has built successful open pit gold mines in Colombia. Any shareholder who would like to discuss Visby's credentials is welcome to contact us at the email below. Given that approval of the TGC option requires shareholder approval, Visby encourages shareholders to vote in their best interest at the upcoming AGM and reject the TCG proposal so that Visby's superior option is considered.
ContactPresidentRoy Ostrom IIIVisby Managementinfo@visbymgmt.com
Photo: https://mma.prnewswire.com/media/2700791/Visby.jpg
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
5 days ago
- Malaysian Reserve
Telix's Illuccix® PSMA-PET Imaging Agent Approved in Portugal
MELBOURNE, Australia, June 4, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix', 'the Company') today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Portugal by INFARMED[2] for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval enhances the options available to healthcare providers across Portugal for PSMA-PET[3] imaging using a clinically validated gallium-based radiopharmaceutical. Illuccix, after radiolabelling with gallium-68, is indicated in Portugal for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings: Primary staging of patients with high-risk PCa prior to primary curative therapy. Suspected recurrent PCa in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy. Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom PSMA-targeted therapy is indicated. PSMA-PET imaging represents a significant advancement in prostate cancer management, largely replacing conventional imaging methods such as bone scans and CT[4] scans as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines recognise its superior accuracy in staging primary disease and assessing BCR[5]. Illuccix® PSMA-PET will help address an important clinical need by supporting timely and effective diagnosis, as well as identifying patients who may benefit from PSMA-targeted therapy. Illuccix's broad approval is supported by robust clinical data, including the largest Ga-68-based PSMA data set from the VISION trial[6]. Despite the proven benefits of PSMA-PET imaging, patients in Portugal have faced long wait times due to tracer shortages and infrastructure constraints. Dr. Fernando Abreu, Director of Nuclear Medicine at the Santa Maria Local Health Unit, commented, 'PSMA-PET imaging has significantly enhanced the accuracy and confidence in the detection and monitoring of prostate cancer. However, Portugal is currently facing a shortage of gallium-68 tracers, which has resulted in a national waiting list of up to six months. This delay has an impact on the timely diagnoses and treatments impacting patient care. The approval of Illuccix® in Portugal will be welcomed by physicians and patients as it allows hospitals and clinics to conduct PSMA-PET scans more efficiently, and with shorter wait times.' With its broad indication, Illuccix® is designed to support healthcare providers in delivering efficient and reliable imaging. The approval comes as demand for PSMA-PET continues to grow across Europe, reinforcing the need for solutions that fit within existing hospital workflows. Illuccix® will be distributed in Portugal by Sociedade Avanço, Unipessoal, LDA (Avanço), a specialist distributor of nuclear medicine, radiotherapy technologies and urology biopsy products. 'The approval of Illuccix® in Portugal marks an important milestone, providing healthcare professionals with access to a gallium-based PSMA-PET imaging agent supported by strong clinical validation. Our partnership with Avanço will help address the current shortages of gallium tracers and enable more efficient scanning processes. This collaboration reflects Telix's ongoing commitment to expanding access to high-quality prostate cancer imaging across Europe and reducing the barriers that currently delay diagnosis and treatment.' said Raphaël Ortiz, Chief Executive Officer, Telix International. Mr. Diogo Marcos, Managing Director of Avanço added: 'We are delighted to partner with Telix for the distribution of Illuccix® in Portugal. As the official distributor of the GalliaPharm®[7] generator, currently the only generator with marketing approval in the country, we are uniquely positioned to help address the national shortage of gallium-68. Our established distribution network ensures nationwide access, and our collaboration with Telix will enable us to support physicians in delivering timely and accurate PSMA-PET imaging.' Healthcare professionals in Portugal interested in ordering Illuccix® or learning more about availability can contact comercial@ or call (+351) 214 380 690. Prostate Cancer in Portugal Prostate cancer is the most common cancer in men in Portugal, with just over 7,500 new cases diagnosed annually, and a significantly higher incidence in men than either bowel (6,092 new cases) or lung cancer (4,253 new cases). Prostate cancer is also the third most common cause of cancer death in men, with just over 2,080 men dying from their disease in Portugal in 2022[8]. About Illuccix® Telix's prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the United States Food and Drug Administration (FDA)[9], by the Australian Therapeutic Goods Administration (TGA)[10], by Health Canada[11], by the Brazilian Health Regulatory Agency (ANVISA)[12], by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)[13], by the French National Agency for the Safety of Medicine and Health Products (ANSM)[14] and in multiple countries within the European Economic Area (EEA)[15] following a positive decentralized procedure (DCP) opinion by the German medical regulator, BfArM[16]. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. [1] Positron emission tomography. [2] National Authority of Medicines and Health Products, I.P. [3] Imaging of prostate-specific membrane antigen with positron emission tomography. [4] Computed tomography. [5] European Association of Urology (EAU) Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3.: Prostate cancer: European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2023: [6] ID: NCT03511664. VISION study sponsored by Endocyte, a Novartis company. Telix provided Illuccix (TLX591-CDx) for PSMA-PET imaging. [7] GalliaPharm® is a registered trademark of Eckert & Ziegler SE. [8] Global Cancer Statistics 2022: GLOBOCAN survey. Published August 2024. [9] Telix ASX disclosure 20 December 2021. [10] Telix ASX disclosure 2 November 2021. [11] Telix ASX disclosure 14 October 2022. [12] Telix ASX disclosure 18 March 2025. [13] Telix ASX disclosure 13 February 2025. [14] Telix media release 29 April 2025. [15] Czech Republic, Denmark, Finland, Ireland, Luxembourg, Malta, the Netherlands, Norway, Portugal and Sweden at time of release. [16] Telix ASX disclosure 17 January 2025. Logo – View original content:
Malaysian Reserve
7 days ago
- Malaysian Reserve
Visby Management Reiterates Superior Offer to LCL Resources
Total Cash Consideration of AUD $15 Million + 1% NSR Visby Urges Shareholders to Reject Tiger Gold Proposal MEDELLIN, Colombia, June 2, 2025 /PRNewswire/ — Visby Management LLC ('Visby'), an international mine operator with operations in Colombia, would like to reiterate its superior, binding offer to acquire the Colombian assets of Los Cerros Limited (ASX: LCL) ('LCL') and is urging LCL shareholders to vote against the proposed transaction with Tiger Gold Corporation ('TGC') at the AGM on June 9, 2025. Visby also encourages shareholders to communicate their support for Visby's proposal at the upcoming LCL public webinar to be held on June 5, 2025. Visby has submitted multiple binding offers to LCL to acquire the company's Colombian assets. In February 2025, Visby presented LCL with a superior offer and encouraged shareholders to vote against the latest TGC offer so that the company could consider it. Subsequently, 84% of shareholders at the February shareholder meeting voted against the TGC offer. Visby has since approached LCL with multiple offers superior to what TGC has offered but the LCL board has consistently refused to engage in discussions or allow shareholders to evaluate Visby's superior offers. Despite a clear message from shareholders in February, the LCL board is again recommending shareholders vote in favor of TGC at the upcoming June 9, 2025 AGM. In hopes of getting support from understandably disgruntled shareholders, LCL scheduled a webinar for June 5, 2025 to presumably persuade shareholders on the TGC sale option. Upon learning of the webinar, Visby requested the opportunity to present its offer to shareholders in this same forum. The LCL board refused Visby's offer. So that shareholders may make the most informed vote at the upcoming AGM, Visby would like to reiterate the following points: The proposed TGC transaction is an option with only AUD $1m upfront, as LCL has stated on multiple occasions, and there is no guarantee TGC will deliver on the second payment due in eight months. Despite an intentional lack of clarity from LCL's board, the TGC option does require shareholder approval. The TGC agreement may be binding, but only as long as shareholders approve it. With these points in mind, Visby would like to reiterate its binding AUD $15 million offer which includes: Upfront payment of AUD $7.5 million (proof of funds available) AUD $7.5 million on first gold pour 1% NSR Visby is an experienced mine operator which has built successful open pit gold mines in Colombia. Any shareholder who would like to discuss Visby's credentials is welcome to contact us at the email below. Given that approval of the TGC option requires shareholder approval, Visby encourages shareholders to vote in their best interest at the upcoming AGM and reject the TCG proposal so that Visby's superior option is considered. ContactPresidentRoy Ostrom IIIVisby Managementinfo@ Photo:
Malaysian Reserve
27-05-2025
- Malaysian Reserve
Kalkine Australia: Financial Research Intelligence for Every Investor
SYDNEY, May 27, 2025 /PRNewswire/ — Kalkine Australia, a subscription-based equity research platform, is advancing the delivery of financial research through its technology-driven approach. Built on a robust digital infrastructure and supported by advanced data science capabilities, the platform offers independent insights into ASX-listed equities for a broad range of investors. Kalkine's model is designed to simplify investment research by transforming market data into structured, actionable intelligence. Through its proprietary platforms, Kalkine provides general advice in the form of Buy, Sell, or Hold stock recommendations, enabling subscribers to make informed investment decisions based on comprehensive analysis. Key Research Offerings Kalkine Australia's services include: Stock Recommendation Reports – Detailed fundamental research on Australian equities. Thematic Insights – Sector-focused studies on areas such as technology, tariffs, clean energy, healthcare, and real estate. Technical Analysis Reports – Chart-based evaluations for short- and medium-term trading strategies. IPO and Dividend Reports – Research on new listings and dividend-paying entities. Model Portfolios – Strategically built portfolios based on value, growth, and momentum investing principles. Stock Screeners – Interactive tools to filter stocks by various technical, fundamental, or thematic criteria. A Comprehensive Stock Selection Framework Kalkine's research methodology is anchored in economic and company-level fundamentals. The team incorporates macroeconomic indicators—such as inflation trends, interest rate shifts, and GDP forecasts—into its stock screening and valuation processes. The platform draws upon traditional principles of value investing, while also adapting to modern market conditions with growth and hybrid models. This blended approach enables the identification of opportunities that may not be immediately visible in broader market narratives. Reports are delivered via a streamlined digital interface available across web and mobile, ensuring that subscribers have access to professional-grade research tools on demand. A Technology-First Approach to Investor Empowerment Kalkine's data-driven platform is designed to support informed decision-making through a combination of analysis tools and expert commentary. By integrating fundamental, technical, and thematic perspectives, the platform helps users build a structured approach to navigating equity markets. About Kalkine Operating across Australia, the United States, the United Kingdom, Canada, India, and New Zealand, Kalkine delivers independent research designed to enhance investor understanding and engagement. The company continues to innovate in the field of equity intelligence by offering accessible and technology-enabled research tools.
